30 results about "Seroconversion" patented technology

Genes encoding herpes simplex virus type 2 (HSV-2) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. In a DNA titration, it was found that a single immunization of ≧0.5 μg of (one) PNV, gave >90% seroconversion by ten weeks post immunization. Immune antisera neutralized both HSV-2 and HSV-1 in cell culture. When animals were challenged with HSV-2, significant (p<0.001) protection from lethal infection was achieved following PNV vaccination. DNA constructs may be full-length, truncated and/or mutated forms and may be delivered along or in combination in order to optimize immunization and protection from HSV infection.

Methods of detecting, diagnosing, monitoring or managing an XMRV-related disease such as an XMRV-related neuroimmune disease such as chronic fatigue syndrome or an XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity of antibodies against XMRV in a sample from a subject.

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.

The invention discloses a recombinant S1 protein of a novel mutant strain of a porcine epidemic diarrhea virus and a subunit vaccine of the recombinant S1 protein. The protein is obtained by the steps of cloning a fusion gene fragment PE(delta III)-S1(m)-KDEL3 containing a KDEL3 gene sequence, a gene sequence of III-region-deleted pseudomonas aeruginosa exotoxin A and an S1(m) gene sequence to a baculovirus vector to obtain a recombinant vector; carrying out recombinant vector site specificity transposition on a seroconversion DH10Bac competent cell of the recombinant vector to obtain a recombinant bacmid; transfecting the recombinant bacmid to an Sf9 cell under the mediation of a liposome to obtain a recombinant Sf9 cell; expressing by using the recombinant Sf9 cell. According to the invention, a PE(delta III)-S1(m)-KDEL3 fusion protein is firstly expressed by using a baculovirus expression system on the basis of optimizing the predilection of a codon of mammalian with S1 genes, so that the recombinant baculovirus for efficiently and accurately expressing the fusion protein is obtained. Proved by IFA and Western blot, the recombinant baculovirus can be used for accurately expressing the fusion protein, and the fusion protein has favorable reactionogenicity.

The invention relates to virosome-based influenza vaccines for the manufacture of medicaments that are administered intradermally in humans. The invention provides (trivalent) compositions comprising low doses of hemagglutinin (HA) antigen in a virosomal preparation that fulfill the immune response standards with respect to seroconversion rates, GMT-fold increase and protection rates, for use in vaccination set-ups.

The present invention proposes a novel mumps vaccine comprising a homogeneously purified isolate derived from the Jeryl-Lynn strain of mumps virus. The vaccine in the preferred embodiment of the invention produces higher seroconversion rates and antibody titers than known commercial vaccines.

An embodiment of the invention provides a processing method for predicting an e-antigen seroconversion rate and a device thereof. The method comprises the steps of acquiring an age and detecting indexparameters of a to-be-predicted patient; wherein the detecting index parameters comprise alanine aminotransferase, glutamic oxaloacetic transaminase, globulin, alkaline phosphatase and hepatitis b e-antigen titer; inputting the age and the detecting index parameter into a preset model, using the output result of the preset model as an e-antigen seroconversion rate predicting result of the to-be-predicted patient in a preset time period; wherein the preset model is constructed based on ANN. The device executes the method. According to the processing method for predicting the e-antigen seroconversion rate and the device, through using the output result of the preset model which is constructed based on ANN as an e-antigen seroconversion rate predicting result of the to-be-predicted patient in the preset time period, accuracy in predicting the e-antigen seroconversion rate can be improved.

The invention relates to medicinal use of liposomes for the treatment of chronic viral hepatitis B, wherein said liposomes are prepared from phospholipid and cholesterol. This invention further relates to uses of said liposomes for the manufacture of medicaments for promoting the seroconversion of Hepatitis B e antibody to positive and the seroconversion of Hepatitis B e antigen to negative in patients with chronic viral hepatitis B, for reducing the hepatitis B virus titer in the peripheral blood serum of patients with chronic viral hepatitis B, for reducing the concentration of glutamic-pyruvic transaminase in the peripheral blood serum of patients with chronic viral hepatitis B, and for maintaining the stability of the T cell receptor repertoire in patients with chronic viral hepatitis B.

The invention relates to the field of traditional Chinese medicine, in particular to a hepatitis B virus resistant traditional Chinese medicine composition composed of the following concrete components in parts: 15-20 parts of radix astragali, 12-15 parts of bupleurum, 12-15 parts of phellodendron bark, 6-12 parts of picrorhiza rhizome, 15-20 parts of giant knotweed, 15-20 parts of dyers woad leaf, 15-20 parts of asket fern, 12-15 parts of white atractylodes rhizome, 15-20 parts of tuckahoe, 15-20 parts of oldenlandia diffusa, 15-20 parts of red sage root and 5-8 parts of liquorice. The hepatitis B virus resistant traditional Chinese medicine composition can be prepared into capsules, decoction or extract, has the effects of clearing away heat and toxic material, strengthening the spleen and removing dampness through diuresis, has very strong efficacies of resisting hepatitis B virus, reducing HBVDNA (Hepatitis B Virus Deoxyribose Nucleic Acid) and promoting seroconversion of HBsAg (Hepatitis B Surface Antigen), and has multiple effects of protecting the liver, preventing pathological changes and the like.

The present invention provides a method for determining the time of infection, and a method for determining if a microbial infection is in the early stages comprising the step of determining the ratio of in vitro stimulated anti-microbial immunoreactivity and un-stimulated anti-microbial immunoreactivity in blood samples from said subject and related kits.

A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and antibody titres than known commercial vaccines.

The invention relates to a process for preparing a novel influenza vaccine, belonging to the technical field of preparation technology of vaccine. The invention comprises that influenza viruses of A1 and A3 of hypotype and B-type are diluted via virus nutrient solution and are individually inoculated mammal cells which grows to single layer according to 1:10 <-1> -1:10 <-7>, yielding virus liquid which contains the influenza viruses. After being deactivated and purified, each virus primary liquid is obtained. The antigen content of each virus primary liquid is detected. The antigen contents of the virus primary liquids of influenza viruses of A1 and A3 of hypotype and B-type are respectively regulated to prepare the vaccine. The invention has the advantage that by employing the mammal cells to produce the influenza vaccines, the animal immunogenicity experiments of the product show that 15 micrograms of hemagglutinin is capable of enabling serums of all experimental animals to be in seroconversion, and the HI antibody titers are all over 1:40.